Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is MOTS-c? Benefits, Research & Safety
A mitochondrial-derived peptide that regulates metabolic homeostasis and exercise adaptations, representing a novel class of signalling molecules.
Also known as:
Mitochondrial ORF of the 12S rRNA Type-c
Mitochondrial-Derived Peptide
UK summary: Not a licensed UK medicine. Mitochondrial-derived peptide studied largely in preclinical animal and cell models. Sold by some online retailers as 'research only'. Likely captured by WADA's S0 non-approved substances category.
Quick Facts
Category
Longevity & Anti-Ageing
Half-Life
Limited human pharmacokinetic data available
UK Status
Not licensed for human use. Research compound only.
EU Status
Not approved for therapeutic use.
Overview
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid peptide encoded within the mitochondrial genome. Discovered in 2015 by researchers at the University of Southern California led by Dr. Pinchas Cohen, MOTS-c represents a novel class of signalling molecules—mitochondrial-derived peptides (MDPs).
Unlike most peptides which are encoded by nuclear DNA, MOTS-c is encoded by the mitochondrial 12S rRNA gene. This discovery challenged the traditional view that mitochondria primarily function as cellular powerhouses and revealed their role as signalling organelles.
MOTS-c has been shown to regulate metabolic homeostasis, enhance insulin sensitivity, and promote the beneficial effects of exercise. Research suggests it acts as an exercise mimetic—producing some of the metabolic benefits of physical activity even without exercise.
The peptide's levels appear to decline with age, and exercise increases its expression and secretion. This has generated significant interest in MOTS-c as a potential therapeutic for age-related metabolic dysfunction, type 2 diabetes, and as an exercise enhancement strategy.
MOTS-c remains in early research stages and is not approved for therapeutic use.
Evidence standards summary
MOTS-c — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.
Not a licensed UK medicine. Mitochondrial-derived peptide studied largely in preclinical animal and cell models. Sold by some online retailers as 'research only'. Likely captured by WADA's S0 non-approved substances category.
02Human evidence grade
ETheoretical / insufficientStrength of evidence from published human trials.
03Preclinical evidence grade
CLimited human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for therapeutic use.
- Notes: MOTS-c is an early-stage research compound. Human clinical trials are in planning stages. Not available through legitimate medical channels.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Reverses biological ageing at the mitochondrial level.
- Acts as a complete substitute for cardio exercise.
- Boosts metabolism and burns visceral fat without diet change.
- Restores insulin sensitivity in type 2 diabetes.
07Common internet claims
- Exercise in a vial — the mitochondrial peptide bodybuilders take.
- Marketed as an anti-ageing breakthrough by longevity influencers.
- Sold as research-only with dosing protocols copied from rodent studies.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Reverses biological ageing” | E | No | High | Preclinical models show effects on mitochondrial metabolism; ageing-reversal claims in humans are not supported. |
| “Mimics the effects of exercise” | D | Limited | Moderate | Animal evidence suggests overlap with some exercise-related signalling; this does not equal substituting for exercise in humans. |
| “Boosts metabolism and burns fat” | D | No | High | Preclinical metabolic effects; human weight-loss claims are not established. |
| “Safe research peptide for personal use” | E | No | High | Long-term human safety is not established. 'Research only' labelling does not address UK regulatory questions about human-use marketing. |
09Safety uncertainty score
High
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Injection site reactions reported anecdotally.
- Unknown systemic effects from sustained AMPK activation in humans.
- Theoretical interaction with metformin and other AMPK-modulating drugs.
- Long-term consequences of exogenous mitochondrial peptide signalling are unstudied in people.
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Sport status unclearWADA strict-liability framing applies.
13UK legal position
UK: Sold as 'research only' (UK)
Not licensed for human use. Research compound only.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Not approved for therapeutic use.
15What this page cannot tell you
- What dose of any online MOTS-c product is safe in humans — there is no licensed reference.
- Whether grey-market vials actually contain the labelled peptide.
- How chronic AMPK activation affects cancer risk, muscle wasting, or insulin signalling long-term.
- Whether it stacks safely with metformin, GLP-1 agonists, or berberine.
16Last reviewed
17Citation quality score
CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- No published Phase 2 or Phase 3 human trials with hard outcomes.
- Pharmacokinetic data in humans is sparse.
- Dose-response relationships for any human endpoint are unestablished.
- Long-term safety entirely unknown.
19Safer alternatives / established care pathways
- Structured aerobic exercise — the actual stimulus MOTS-c is claimed to mimic.
- GP review for metformin if metabolic syndrome or pre-diabetes is the concern.
- Licensed weight-management referral if obesity is the target outcome.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is MOTS-c a licensed UK medicine?
- What does the human evidence look like outside of preclinical mitochondrial research?
- If I'm an athlete, what is the anti-doping position?
- What licensed treatments exist for the metabolic outcomes I'm asking about?
Discovery & History
MOTS-c was discovered in 2015 by the laboratory of Dr. Pinchas Cohen at the University of Southern California (USC) Leonard Davis School of Gerontology. The discovery emerged from research into novel peptides encoded within the mitochondrial genome.
Prior to this discovery, it was believed that mitochondrial DNA primarily encoded components of the electron transport chain and mitochondrial ribosomes. The identification of MOTS-c and other mitochondrial-derived peptides revealed that mitochondria could produce signalling molecules that regulate whole-body metabolism.
The initial publication demonstrated that MOTS-c could prevent age-dependent and diet-induced obesity and insulin resistance in mice. The peptide appeared to work by promoting metabolic homeostasis and activating AMPK (AMP-activated protein kinase), a key metabolic sensor.
Subsequent research showed that MOTS-c is secreted into circulation in response to exercise, suggesting it may mediate some of exercise's beneficial metabolic effects. Studies also revealed that MOTS-c levels decline with age, potentially contributing to age-related metabolic dysfunction.
Research into MOTS-c and other mitochondrial-derived peptides continues, representing an exciting new area of metabolism and ageing research.
Mechanism of Action
MOTS-c exerts its metabolic effects through several mechanisms:
**AMPK Activation**
MOTS-c activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while inhibiting energy-consuming processes.
**Nuclear Translocation**
Remarkably, MOTS-c can translocate to the nucleus in response to metabolic stress, where it may directly regulate gene expression. This represents an unusual signalling mechanism for a mitochondrial-derived peptide.
**Glucose Metabolism**
MOTS-c enhances glucose uptake and utilisation by skeletal muscle, improving overall glucose homeostasis. It appears to promote the metabolic adaptations typically associated with exercise training.
**Folate-Methionine Cycle Regulation**
The peptide influences one-carbon metabolism through effects on the folate-methionine cycle, which is important for various biosynthetic and regulatory processes.
**Exercise Mimetic Effects**
MOTS-c reproduces some of the metabolic benefits of exercise, including improved insulin sensitivity and altered substrate utilisation. Exercise increases MOTS-c secretion, suggesting the peptide may mediate some exercise benefits.
**Stress Response**
MOTS-c appears to enhance cellular stress resistance, potentially contributing to the health-promoting effects of exercise and metabolic adaptation.
Researched Benefits
Based on preclinical and clinical research findings:
- 1Improved insulin sensitivity in animal models
- 2Prevention of diet-induced obesity in mice
- 3Enhanced glucose metabolism and uptake
- 4Activation of AMPK and metabolic regulation
- 5Exercise mimetic effects on metabolism
- 6Potential role in healthy ageing
- 7Improved mitochondrial function
Claim vs Evidence
How popular claims about MOTS-c stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Reverses biological ageing” | E | No | High | Preclinical models show effects on mitochondrial metabolism; ageing-reversal claims in humans are not supported. |
| “Mimics the effects of exercise” | D | Limited | Moderate | Animal evidence suggests overlap with some exercise-related signalling; this does not equal substituting for exercise in humans. |
| “Boosts metabolism and burns fat” | D | No | High | Preclinical metabolic effects; human weight-loss claims are not established. |
| “Safe research peptide for personal use” | E | No | High | Long-term human safety is not established. 'Research only' labelling does not address UK regulatory questions about human-use marketing. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Not established; animal studies use various weight-based doses |
| Frequency | Variable in research settings |
| Duration | Not established for human use |
| Notes | MOTS-c is in early research stages without established human protocols. Any information on dosing should be considered highly experimental. Human clinical trials are needed to determine appropriate use. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (in animal research)
- Intraperitoneal injection (animal models)
| Half-Life | Stability |
|---|---|
| Limited human pharmacokinetic data available | Peptide stability data from research settings |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Limited safety data in humans
- Animal studies suggest generally well-tolerated
Rare Risks & Concerns
- Unknown long-term effects
- Effects on cancer cells uncertain
- Metabolic effects in diabetics could require medication adjustment
Contraindications
- Diabetes (potential blood glucose effects)
- Pregnancy and breastfeeding
- Active malignancy (effects unknown)
- Children and adolescents
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
MOTS-c is an early-stage research compound. Human clinical trials are in planning stages. Not available through legitimate medical channels.
Clinical Studies Summary
MOTS-c: A Mitochondrial-Derived Peptide Regulating Metabolic Homeostasis
Discovery paper demonstrating MOTS-c's role in metabolic regulation and prevention of obesity and insulin resistance in mice.
Cell Metab. 2015;21(3):443-54View on PubMed
The Mitochondrial-Derived Peptide MOTS-c is Regulated by Exercise
Research showing exercise-induced increase in MOTS-c and its role in exercise adaptations.
Am J Physiol Endocrinol Metab. 2016View on PubMed
Looking for MOTS-c?
Source research-grade MOTS-c from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about MOTS-c
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is MOTS-c a licensed UK medicine?
- What does the human evidence look like outside of preclinical mitochondrial research?
- If I'm an athlete, what is the anti-doping position?
- What licensed treatments exist for the metabolic outcomes I'm asking about?
UK regulatory & safety context
Related Research Guides
Related Peptides
GHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn moreEpitalon
A synthetic tetrapeptide based on epithalamin, researched for its potential effects on telomerase activation and biological ageing.
Learn moreHumanin
A mitochondrial-derived peptide with cytoprotective and anti-apoptotic properties, researched for neuroprotection, metabolic regulation, and ageing.
Learn more